Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 2Thoracic 1Gynecologic 1Genitourinary 1Breast 1

Conditions

Urinary Bladder Neoplasms 157Carcinoma, Transitional Cell 56Non-Muscle Invasive Bladder Neoplasms 30Urethral Neoplasms 24Carcinoma, Renal Cell 23Neoplasms 19Kidney Neoplasms 15Pancreatic Neoplasms 14Ovarian Neoplasms 14Neoplasm Metastasis 13Carcinoma, Non-Small-Cell Lung 13Prostatic Neoplasms 12Ureteral Neoplasms 11Urologic Neoplasms 9Colorectal Neoplasms 9Breast Neoplasms 9Lung Neoplasms 7Testicular Neoplasms 6Stomach Neoplasms 6Melanoma 6Sarcoma 5Urothelial Cancer 4Squamous Cell Carcinoma of Head and Neck 4Small Cell Lung Carcinoma 4Osteosarcoma 4Colonic Neoplasms 4Urogenital Neoplasms 3Triple Negative Breast Neoplasms 3Recurrence 3Parkinson Disease 4, Autosomal Dominant Lewy Body 3

Interventions

tivozanib 1grapiprant 1Tamsulosin 1Standard of Care 1Radiosurgery 1Practice Guidelines as Topic 1Palliative Care 1Nivolumab 1Multiparametric Magnetic Resonance Imaging 1Lycopene 1Gemcitabine 1Epirubicin 1Cystectomy 1Clinical Trials, Phase II as Topic 1Clinical Trials, Phase I as Topic 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Disease Progression × Gemcitabine × Genitourinary × Clear all
NCT02538432 2019-11-04

Phase II Trial of EP4 Receptor Antagonist, AAT-007 (RQ-07; CJ-023,423) in Advanced Solid Tumors

University of Maryland, Baltimore

Phase 2 Withdrawn
BreastGenitourinaryThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Prostatic Neoplasms, Disease Progression

Data powered by HemOnc (CC BY 4.0) Colophon âš¡